2018 ASH Annual Meeting & Exposition
James Douketis, MD, McMaster University, Hamilton, Ontario, discusses the the PAUSE (the Perioperative Anticoagulant Use ...
During the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego in December 2018, Peter ...
At the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, Aziz Nazha, MD of Cleveland Clinic ...
Mitchell Cairo, MD, Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation; Director of the Children and ...
According to updated data from the phase II JULIET trial presented at the 2018 ASH Annual Meeting, the chimeric antigen ...
Jonathan U. Peled, MD, of Memorial Sloan Kettering Cancer Center discusses his study which looked at whether pre-HCT ...
Erica B. Esrick, MD, Hematologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reported on her ...
Richard Thomas Maziarz, MD discusses the JULIET trial at the American Society of Hematology (ASH) Annual Meeting and ...
According to an update presented at the ASH annual meeting, tisagenlecleucel (Kymriah, Novartis) produced high response ...
Some patients receiving low-molecular-weight heparin (LMWH) such as enoxaparin benefit from routine laboratory ...
The most common reason children with sickle cell disease (SCD) are hospitalized is pain crisis, and hospitalizations ...
Chimeric antigen receptor (CAR) T-cell therapy has been shown to lead to high rates of complete response in relapsed ...
JCAR014 is a CD19-specific chimeric antigen receptor (CAR)-modified T-cell therapy developed by Juno Therapeutics. ...
Patients with cancer are at an increased risk of blood clots. Research presented at the 2018 ASH Annual Meeting showed ...
Luspatercept produced a clinically meaningful reduction of red blood cell (RBC) transfusions and was generally well ...
Michael Hallek, MD, of University Hospital, Cologne, Germany, delivered the Ham-Wasserman Lecture, titled “On the ...
Use of a Geriatric Assessment in Hematology (GAH) scale, used to classify patients according to frailty phenotype, has ...
The integration of mobile health technology for symptom management in acute pediatric blood and marrow transplant (BMT) ...
A proof-of-principle study has shown that cells edited to remove the genetic mechanisms for turning down the production ...
Marco L. Davila, MD, associate attending physician in the Department of Blood & Marrow Transplantation and cellular ...
Amy Burd, PhD discussed the Leukemia & Lymphoma Society (LLS)-led Beat AML trial, which was designed to assess ...
The presence of an oncology pharmacist could help to improve safety when patients with leukemia are transferring from ...
A study of risk distribution scores for patients with chronic myeloid leukemia (CML) indicated that risk distribution ...
Real-world patients with chronic myeloid leukemia (CML) are often different from the ones selected for clinical trial ...
Long-term data from the MURANO study indicated that patients with relapsed or refractory chronic lymphocytic leukemia ...
Undertreated iron overload in patients with sickle cell disease undergoing chronic transfusion therapy may be an ...
An international group of researchers examined whether microbiota configuration prior to hematopoietic cell ...
Thromboembolism is a leading cause of death in people with cancer. A presentation at the ASH annual meeting reviewed a ...
A group of international researchers at the ASH annual meeting presented results from the Medalist Trial, which is ...
According to the National Cancer Institute, a tumor board review is “a treatment-planning approach in which a number ...
Early results from the Beat AML Master Trial confirmed the feasibility of a precision medicine treatment assignment in ...
Tailoring the treatment of multiple myeloma with molecular-oriented treatments was associated higher response rates and ...
Treatment with ibrutinib resulted in improved progression-free survival (PFS) for older patients with chronic ...
Despite an increase in hospitalization rates among most age groups of adults with sickle cell disease, there has been no ...
Patients with high-risk sickle cell disease had significantly improved health-related quality of life (QOL) and remained ...
Multidisciplinary care achieved by incorporating another sub-specialized provider increased adherence to core supportive ...
The majority of patients with diffuse large B-cell lymphoma (DLBCL) would have been eligible for treatment with chimeric ...
CT-P10 (Truxima™, Celltrion Healthcare), a biosimilar to anti-CD20 antibody rituximab, was therapeutically equivalent ...
Results of a proof-of-principle study demonstrated the feasibility of using a microRNA-adapted shRNA (shRNAmiR) ...
Use of hydroxyurea reduced sickle-related clinical events, transfusion, malaria, and death in a population of children ...
Patients with leukemia often transition between inpatient and outpatient settings, which may interrupt attention to ...
A vaso-occlusive crisis, or sickle cell crisis, is a common and painful complication of sickle cell disease (SCD). ...
CT-P10 (Truxima™, Celltrion Healthcare) is the first biosimilar of the reference monoclonal anti-CD20 antibody ...
Chronic lymphocytic leukemia (CLL) is a disease of older adults, with a median age of onset of about 70 years. ...
β-thalassemia is a blood disorder that reduces the production of hemoglobin. It is an inherited hemoglobinopathy ...
It is known that somatic genomic alterations contribute to the pathogenesis of acute myeloid leukemia (AML), but the ...
ASH President Alexis Thompson, MD, MPH, welcomed participants with the following address: ...
This year’s Ham-Wasserman Lecture will be delivered by Dr. Michael Hallek (Department I of Internal Medicine and ...
This year’s Plenary Scientific Session will be held on Sunday, December 2, from 2:00-4:00pm in Hall AB. According to ...
Advertisement
Advertisement
